National Kidney Foundation Statement on CREDENCE Data as Potential New Treatment for Diabetic Kidney Disease


Quotes for attribution to National Kidney Foundation

NEW YORK, April 14, 2019 /PRNewswire/ — “Data from the CREDENCE trial published today in the New England Journal of Medicine demonstrate that INVOKANA® (Canagliflozin) can help reduce the risk of end stage renal disease (ESRD) and cardiovascular events in patients already diagnosed with Type 2 diabetes and chronic kidney disease (CKD). If this supplemental indication is approved by the Food and Drug Administration (FDA), it would be the first new treatment for diabetic kidney disease (DKD) in decades.”

NKF Logo (PRNewsfoto/National Kidney Foundation)

“CKD is a largely invisible and growing public health problem with limited treatment options available. Today’s study announcement is encouraging for patients with diabetic kidney disease and an important step forward to staving off ESRD. Once a patient progresses to ESRD, dialysis or a kidney transplant is needed to survive. It is important for patients to note that while this announcement is promising, patients should continue to consult with their doctors on an appropriate treatment for them.”

“Diabetes is a key risk factor for chronic kidney disease, and accounts for 44% of all end stage renal disease cases. However less than 40% of those with diabetes are completely assessed for kidney disease. Two simple tests, an eGFR (which assesses kidney function) and an ACR (which assesses kidney damage) can diagnose kidney disease, and these tests results are also strong predictors of cardiovascular risk. For more information about CKD, diabetes and cardiovascular risk, see NKF’s comprehensive “Chronic Kidney Disease Change Package: Population Health Strategies for Cardiovascular and Kidney Disease Risk Reduction” report for clinicians and public health practitioners announced in January 2019.”

Kidney Disease Facts

In the United States 30 million adults are estimated to have chronic kidney disease—and most aren’t aware of it. 1 in 3 American adults are at risk for chronic kidney disease. Risk factors for kidney disease include diabetes, high blood pressure, heart disease, obesity and family history. People of African American, Hispanic, Native American, Asian or Pacific Islander descent are at increased risk for developing the disease. African Americans are 3 times more likely than Whites, and Hispanics are nearly 1.5 times more likely than non-Hispanics to develop end stage renal disease (kidney failure).

The National Kidney Foundation (NKF) is the largest, most comprehensive and longstanding organization dedicated to the awareness, prevention and treatment of kidney disease. For more information about NKF visit www.kidney.org.

Facebook.com
Twitter:@NKF
www.kidney.org

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/national-kidney-foundation-statement-on-credence-data-as-potential-new-treatment-for-diabetic-kidney-disease-300831789.html

SOURCE National Kidney Foundation





Source link Diabetes Information

About alldiabetes 2779 Articles
At alldiabetes, our mission is to help your local business grow and thrive. We take a unique approach, combining award-winning technology with expert service to drive performance based on your goals. It starts with understanding your business and building a plan to help grow your business through online marketing. We use our data, expertise, insights, and best practices to build the right online marketing plan for your unique business needs. What do you want to accomplish through marketing your local business online? Whatever your goals, we’ve got the tactics and the team to drive results. Let us focus on your marketing, so you can focus on running your business. alldiabetes Team

Leave a Reply

Your email address will not be published.


*


Shares